cancer research
cancer research

Revolutionary Munich Company Doses First Patient with Groundbreaking Cancer Treatment
BIOT
📢 Tubulis from Munich doses first patient with its ADC candidate TUB-040 targeting NaPi2b antigen in ovarian and lung cancer. 🧪

Revolutionary Organoid Models Boost Cancer Therapy
BIOT
Organoid-Immune Co-Culture Models for Cancer Research explores the potential of organoids to revolutionize cancer therapy. 🧪🩺🌱🤝🚀💊






